



Boston, United States  
Sydney, Australia  
30 April 2020 AEST

## GI Dynamics Files an Amendment to the Annual Report on SEC Form 10-K

**BOSTON and SYDNEY — 30 April 2020** — GI Dynamics® Inc. (ASX:GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, announces today that it has filed an amendment to its Annual Report on Form 10-K as required by the United States Securities and Exchange Commission.

The purpose of the amendment is to amend Part III, items 10 through 14 of the Original Form 10-K, to provide information previously included by reference of the Company's definitive proxy statement into Part III of the Original Form 10-K. An amendment is required to provide this information, as the definitive proxy statement containing the information will not be filed within 120 days of the end of the reporting period for the Annual Report. In addition, new certifications by the Company's principal executive officer and principal financial officer are filed as exhibits to this amendment.

This announcement has been authorized for release by Charles Carter, chief financial officer and company secretary of GI Dynamics.

### **About GI Dynamics**

GI Dynamics®, Inc. (ASX:GID) is the developer of EndoBarrier®, the first endoscopically-delivered medical device for the treatment of type 2 diabetes and the reduction of obesity. EndoBarrier is not approved for sale and is limited by federal law to investigational use only. EndoBarrier is subject to an Investigational Device Exemption by the FDA in the United States and is entering concurrent pivotal trials in the United States and India.

Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information please visit the Company website at [www.gidynamics.com](http://www.gidynamics.com).

**Chief Financial Officer /  
Secretary**  
United States:  
Charles Carter  
+1 (781) 357-3263  
ccarter@gidynamics.com

**Investor Relations**  
United States:  
Janell Shields  
+1 (781) 357-3280  
investor@gidynamics.com



Boston, United States  
Sydney, Australia  
30 April 2020 AEST

## **Forward-Looking Statements**

This announcement may contain forward-looking statements. These statements are based on management's current estimates and expectations of future events as of the date of the press release. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements.

These risks and uncertainties include, but are not limited to, risks associated with the ability of the Company, its critical vendors, and key regulatory agencies to resume operational capabilities subsequent to the removal of COVID-19 pandemic restrictions; the Company's ability to continue to operate as a going concern; the Company's ability to raise sufficient additional funds to continue operations and to conduct the planned pivotal trial of EndoBarrier in the United States (STEP-1); the Company's ability to maintain compliance with its obligations under its existing convertible note and warrant agreements executed with Crystal Amber, including its obligations to make payment on the convertible note that is due on 1 May 2020 and its ability to restructure the terms of the convertible note with Crystal Amber that is due on 1 May 2020 if the Company is unable to raise sufficient funds to enable it to fully repay such convertible note when due; the Company's ability to execute STEP-1 under the FDA's Investigational Device Exemption; the Company's ability to enlist clinical trial sites and enroll patients in accordance with STEP-1; the risk that the FDA stops STEP-1 early as a result of the occurrence of certain safety events or does not approve an expansion of STEP-1; the Company's ability to enroll patients in accordance with I-STEP; the Company's ability to secure a CE Mark; the Company's obtaining and maintaining regulatory approvals required to market and sell the Company's products; the possibility that future clinical trials will not be successful or confirm earlier results; the timing and costs of clinical trials; the timing of regulatory submissions; the timing, receipt and maintenance of regulatory approvals; the timing and amount of other expenses; the timing and extent of third-party reimbursement; intellectual-property risk; risks related to excess inventory; risks related to assumptions regarding the size of the available market; the benefits of the Company's

### **Chief Financial Officer / Secretary**

United States:  
Charles Carter  
+1 (781) 357-3263  
ccarter@gidynamics.com

### **Investor Relations**

United States:  
Janell Shields  
+1 (781) 357-3280  
investor@gidynamics.com



Boston, United States  
Sydney, Australia  
30 April 2020 AEST

products; product pricing; timing of product launches; future financial results; and other factors, including those described in the Company's filings with the SEC.

Given these uncertainties, one should not place undue reliance on these forward-looking statements. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless it is required to do so by law.

###

**Chief Financial Officer /  
Secretary**

United States:  
Charles Carter  
+1 (781) 357-3263  
ccarter@gidynamics.com

**Investor Relations**

United States:  
Janell Shields  
+1 (781) 357-3280  
investor@gidynamics.com